PHILLIP RODGERS: Open Payments
NPI 1619700481 · DURANT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$514 in 23 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $246 · 2025 $514
Food & beverage: $514
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 10 | $278 |
| Novo Nordisk Inc | 4 | $67 |
| ABBVIE INC. | 2 | $36 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $24 |
| CSL Behring | 1 | $23 |
Products named: FARXIGA, BREZTRI, Ozempic, UBRELVY, AIRSUPRA, TRELEGY ELLIPTA, Kerendia, REXULTI.
Industry payments across MS — which companies pay providers there.
